MedDataX Logo

Database of Interstitial Lung Diseases

NCT ID: NCT00267800

Last Updated: 2008-08-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

100000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2006-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The cause of most interstitial lung diseases (ILDs) is still unknown. Further research, for example to determine predisposing genetic factors, is therefore needed. A database with relevant clinical data and DNA/serum samples of ILD patients could facilitate future research on the cause of ILDs.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Protocol title: 'Registration of clinical data and DNA of patients with Interstitial Lung Disease (ILD)' Rationale: The etiopathogenesis of most Interstitial Lung Diseases (ILDs) is still unknown. Further research, e.g. to determine predisposing genetic factors, is therefore needed. A database with relevant clinical data and DNA/serum samples of ILD patients could facilitate future research on the etiopathogenesis of ILDs.

Objective: Availability of relevant clinical data and DNA/serum samples of ILD patients in a database. Those data can be used for future research.

Study design: A prospective observational study

Study population: Patients diagnosed with ILD attending the pulmonology department in participating hospitals.

Intervention: a blood sample is taken from each patient. Furthermore, additional information is collected from the medical file.

Main study parameters/endpoints: DNA and serum sample, demographic variables, medical information, occupational history and hobbies.

Nature and extent of the burden and risks associated with participation, group relatedness: two tubes of blood will be drawn from the patients. The risks of drawing blood from a vein are minimal.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Interstitial Lung Diseases

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Lung disease, Interstitial Sarcoidosis Pulmonary fibrosis

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of an ILD, as stated by the American Thoracic Society (ATS)
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

St. Antonius Hospital

OTHER

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

J.M.M. van den Bosch, M.D.

Role: PRINCIPAL_INVESTIGATOR

St. Antonius Hospital

J.C. Grutters, M.D.

Role: PRINCIPAL_INVESTIGATOR

St. Antonius Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

St. Antonius Hospital

Nieuwegein, , Netherlands

Site Status

Diakonessenhuis

Utrecht, , Netherlands

Site Status

Mesos Medisch Centrum

Utrecht, , Netherlands

Site Status

UMC Utrecht

Utrecht, , Netherlands

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Netherlands

References

Explore related publications, articles, or registry entries linked to this study.

Drent M, Wijnen PA, Jessurun NT, Harmsze AM, Bekers O, Bast A. Drug-Gene Risk Stratification in Patients with Suspected Drug-Induced Interstitial Lung Disease. Drug Saf. 2024 Apr;47(4):355-363. doi: 10.1007/s40264-024-01400-0. Epub 2024 Mar 9.

Reference Type DERIVED
PMID: 38460070 (View on PubMed)

Jessurun NT, Drent M, Wijnen PA, Harmsze AM, van Puijenbroek EP, Bekers O, Bast A. Role of Drug-Gene Interactions and Pharmacogenetics in Simvastatin-Associated Pulmonary Toxicity. Drug Saf. 2021 Nov;44(11):1179-1191. doi: 10.1007/s40264-021-01105-8. Epub 2021 Oct 4.

Reference Type DERIVED
PMID: 34606062 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

R05.08/A

Identifier Type: -

Identifier Source: org_study_id